Global Alliance for TB Drug Development Grant



Organization - Global Alliance for TB Drug Development
Grant Amount - $450,000
Foundation - Rockefeller Foundation
Grant Purpose - in general support of its mission to halt the rise and reverse the spread of the world's oldest infectious disease by developing new, faster-acting and affordable tuberculosis medicines


Similar Grants

Global Alliance for TB Drug Development - $7,000,000 from the Rockefeller Foundation - in general support of its efforts to develop new, more effective medicines to treat tuberculosis that will be affordable and available in developing countries

Floyd McCree Theatre - $50,000 from the Mott Foundation - This grant will support the expansion of one of the theatre's recent plays, "Graffiti Chronicles," for traveling performances to 18 sites in Flint and Genesee County. This grant will support the production costs of these...

Global Alliance for TB Drug Development - $100,000 from the Rockefeller Foundation - to sponsor its use of the services provided by InnoCentive, Inc. to seek solutions related to its efforts to develop affordable, effective tuberculosis drugs that relieve the disease burden felt by poor people in developing countries

Kenya Education Network Trust - $105,000 from the Rockefeller Foundation - in support of a project to acquire and provide effective management of faster and more affordable bandwidth to a consortium of public and private universities in Kenya

3D-Trade-Human Rights-Equitable Economy - $75,000 from the Rockefeller Foundation - toward the costs of a project that will use human rights rules and mechanisms to ensure access to affordable medicines in developing countries

Recent News from Rockefeller Foundation


Social Enterprise Network Sites


Glasgow Caledonian University (GCU) has launched a series of noteworthy research projects to learn if social enterprises can help Scotland lose its “sick man of Europe” label and boost the nation’s overall health.




Federal Government Grant and Assistance Programs



Edited by: Michael Saunders

© 2008-2025 Copyright Michael Saunders